Targeting Nrf2 Signaling in Friedreich’s Ataxia Cardiomyopathy: Sex-Dependent Therapeutic Responses to Dimethyl Fumarate and Omaveloxolone

Friedreich’s ataxia (FA) is a progressive neurodegenerative disorder frequently associated with hypertrophic cardiomyopathy and heart failure, a major cause of mortality. FA results from frataxin deficiency, leading to mitochondrial dysfunction, impaired iron–sulfur cluster biogenesis, and oxidative stress. We examined the effect of two clinically relevant Nrf2 activators, dimethyl fumarate (DMF) and omaveloxolone (OMAV), on their ability to restore cardiac function in an inducible and reversible frataxin-knockdown (FXNKD) mouse model of FA. FXNKD mice developed a heart failure with preserved ejection fraction–like phenotype, characterized by left ventricular wall thickening, impaired diastolic relaxation, and reduced stroke volume, with more severe remodeling observed in males. Both treatments activated canonical Nrf2 signaling, confirming target engagement. DMF partially improved cardiac function in males, increasing stroke volume, enhancing metabolic flexibility, and restoring mitochondrial enzyme activity; however, diastolic dysfunction persisted. OMAV treatment was associated with female-specific electrophysiological abnormalities, including increased arrhythmic burden and reduced J-wave amplitude, with persistent fibrotic remodeling. Both treatments attenuated region-specific cardiomyocyte atrophy in FXNKD males and females. These findings suggest that Nrf2 activation alone is insufficient to reverse FA-associated cardiomyopathy and reveal sex-dependent therapeutic responses. Further investigation of complementary treatment strategies may help address persistent cardiac dysfunction and remodeling in FA.

Authors

Institutions

Publication Details

Journal
Antioxidants
Published
2026-11-17
DOI
https://doi.org/10.3390/antiox15111490
Primary Topic
Genetic Neurodegenerative Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting Nrf2 Signaling in Friedreich’s Ataxia Cardiomyopathy: Sex-Dependent Therapeutic Responses to Dimethyl Fumarate and Omaveloxolone

Francisco Figueroa, Nipavan Chiamvimonvat, Claire B. Montgomery, Gino A. Cortopassi et al.
2 links
Antioxidants
Genetic Neurodegenerative Diseases
article

Targeting Nrf2 Signaling in Friedreich’s Ataxia Cardiomyopathy: Sex-Dependent Therapeutic Responses to Dimethyl Fumarate and Omaveloxolone

Francisco Figueroa, Nipavan Chiamvimonvat, Claire B. Montgomery, Gino A. Cortopassi, Phung Ngoc Thai, Elena N. Dedkova, Landon C. Sims, Lili Salinas, Ryan Sellers, Garrett P. Cox, Sascha L. Golove
article en

Abstract

Friedreich’s ataxia (FA) is a progressive neurodegenerative disorder frequently associated with hypertrophic cardiomyopathy and heart failure, a major cause of mortality. FA results from frataxin deficiency, leading to mitochondrial dysfunction, impaired iron–sulfur cluster biogenesis, and oxidative stress. We examined the effect of two clinically relevant Nrf2 activators, dimethyl fumarate (DMF) and omaveloxolone (OMAV), on their ability to restore cardiac function in an inducible and reversible frataxin-knockdown (FXNKD) mouse model of FA. FXNKD mice developed a heart failure with preserved ejection fraction–like phenotype, characterized by left ventricular wall thickening, impaired diastolic relaxation, and reduced stroke volume, with more severe remodeling observed in males. Both treatments activated canonical Nrf2 signaling, confirming target engagement. DMF partially improved cardiac function in males, increasing stroke volume, enhancing metabolic flexibility, and restoring mitochondrial enzyme activity; however, diastolic dysfunction persisted. OMAV treatment was associated with female-specific electrophysiological abnormalities, including increased arrhythmic burden and reduced J-wave amplitude, with persistent fibrotic remodeling. Both treatments attenuated region-specific cardiomyocyte atrophy in FXNKD males and females. These findings suggest that Nrf2 activation alone is insufficient to reverse FA-associated cardiomyopathy and reveal sex-dependent therapeutic responses. Further investigation of complementary treatment strategies may help address persistent cardiac dysfunction and remodeling in FA.

AntioxidantsVol. 15(11)
University of Arizona (US), California Northstate University (US), University of California, Davis (US)
American Heart Association, National Institutes of Health, University of California, Davis
Good health and well-being
Genetic Neurodegenerative Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon